A cell-penetrating peptide called T7 was used to load chemotherapy into neutrophils, which then crossed the blood-brain barrier and delivered the drug directly to glioblastoma tumors in mice.
Blood-brain barrier crossedT7 peptide-guided neutrophils successfully penetrated the BBB and delivered temozolomide to glioblastoma sites
What the researchers found
T7-conjugated cholesterol nanoparticle micelles loaded with temozolomide (TMZ) were efficiently taken up by neutrophils. T7 served a dual purpose: as a cell-penetrating peptide to enhance delivery into neutrophils, and as a transferrin-targeting peptide to direct delivery to tumor cells.
When T7/TMZ-conveyed neutrophils were injected intravenously into glioblastoma mouse models, they penetrated the blood-brain barrier and delivered the drug directly to tumor sites. The system demonstrated both efficient drug delivery and therapeutic effects against glioblastoma.
Why it matters
Glioblastoma is the most aggressive brain cancer with a median survival of about 15 months. The blood-brain barrier prevents most drugs from reaching the tumor. Using the body's own immune cells as drug carriers, guided by a targeting peptide, is an elegant solution that could dramatically improve treatment delivery for this devastating disease.
How the study worked
Researchers synthesized T7-cholesterol nanoparticle micelles that self-assembled in aqueous solution and loaded them with temozolomide. These nanoparticles were attached to neutrophil membranes. In vitro experiments confirmed neutrophil uptake, and in vivo experiments in a glioblastoma mouse model evaluated blood-brain barrier penetration, tumor targeting, and therapeutic efficacy after intravenous injection.
What this study cannot tell us
This is a preclinical mouse study, and brain tumor models in mice have historically had limited translation to human outcomes. The specific drug delivery efficiency and therapeutic response metrics were not detailed in the abstract. Long-term survival data, potential immune reactions to modified neutrophils, and scalability of neutrophil harvesting and loading were not addressed.
How to read the evidence
This is a preclinical proof-of-concept study in mice demonstrating a novel drug delivery approach. While the concept is innovative and the results promising, this is early-stage research far from clinical application.
When this study was published
Published in 2024 in ACS Applied Materials & Interfaces, this is a recent contribution to the rapidly evolving field of peptide-mediated drug delivery.
The bigger picture
Cell-penetrating peptides and cell-based drug delivery are two of the most active areas in peptide nanotechnology. This study combines both approaches, using a peptide to hijack immune cells as Trojan horses for delivering chemotherapy past the blood-brain barrier — a strategy that could be adapted for other brain diseases beyond cancer.
Questions still open
- How does the drug delivery efficiency of T7/TMZ-neutrophils compare to conventional temozolomide treatment in glioblastoma models?
- Could this neutrophil delivery system be loaded with other drugs or immunotherapies beyond temozolomide?
- Is the neutrophil harvesting and loading process practical enough for clinical application?
Common questions
What is a cell-penetrating peptide?
Why use neutrophils instead of injecting the drug directly?
Read the original research
Targeted Delivery of Nanoparticle-Conveyed Neutrophils to the Glioblastoma Site for Efficient Therapy.
ACS applied materials & interfaces, 16(32), 41819-41827
Citation
Piao, Chunxian; Lee, Jaeho; Kim, Gi Eun; Choe, Young Ho; Lee, Haerang; Hyun, Young-Min. (2024). Targeted Delivery of Nanoparticle-Conveyed Neutrophils to the Glioblastoma Site for Efficient Therapy.. ACS applied materials & interfaces, 16(32), 41819-41827. https://doi.org/10.1021/acsami.4c05691